These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36410817)

  • 41. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial.
    Pu C; Lei L; Yang F; Deng H; Sheng J; Liu Z; Hu S; Wang L; Wu B; Bo Q; Inoue Y; Yu X
    BMJ Open; 2022 Apr; 12(4):e054079. PubMed ID: 35443947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial.
    Morrison AP; Hutton P; Wardle M; Spencer H; Barratt S; Brabban A; Callcott P; Christodoulides T; Dudley R; French P; Lumley V; Tai SJ; Turkington D
    Psychol Med; 2012 May; 42(5):1049-56. PubMed ID: 21914252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
    Trampush JW; Lencz T; DeRosse P; John M; Gallego JA; Petrides G; Hassoun Y; Zhang JP; Addington J; Kellner CH; Tohen M; Burdick KE; Goldberg TE; Kane JM; Robinson DG; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1237-47. PubMed ID: 26409223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.
    Keefe RSE; Harvey PD; Khan A; Saoud JB; Staner C; Davidson M; Luthringer R
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29873956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.
    Drosos P; Johnsen E; Bartz-Johannessen CA; Larsen TK; Reitan SK; Rettenbacher M; Kroken RA
    World J Psychiatry; 2022 Mar; 12(3):521-532. PubMed ID: 35433321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis.
    Rosengard RJ; Malla A; Mustafa S; Iyer SN; Joober R; Bodnar M; Lepage M; Shah JL
    JAMA Psychiatry; 2019 Jan; 76(1):61-70. PubMed ID: 30304442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subjective cognitive complaints in schizophrenia: relation to antipsychotic medication dose, actual cognitive performance, insight and symptoms.
    Sellwood W; Morrison AP; Beck R; Heffernan S; Law H; Bentall RP
    PLoS One; 2013; 8(12):e83774. PubMed ID: 24376745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia.
    Chiliza B; Asmal L; Kilian S; Phahladira L; Emsley R
    Hum Psychopharmacol; 2015 May; 30(3):173-82. PubMed ID: 25758549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.
    Younis IR; Gopalakrishnan M; Mathis M; Mehta M; Uppoor R; Zhu H; Farchione T
    JAMA Psychiatry; 2020 Oct; 77(10):1064-1071. PubMed ID: 32609294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants.
    O'Donoghue B; Francey SM; Nelson B; Ratheesh A; Allott K; Graham J; Baldwin L; Alvarez-Jimenez M; Thompson A; Fornito A; Polari A; Berk M; Macneil C; Crisp K; Pantelis C; Yuen HP; Harrigan S; McGorry P
    Early Interv Psychiatry; 2019 Aug; 13(4):953-960. PubMed ID: 30024100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
    F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
    Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcranial magnetic stimulation (TMS) for schizophrenia.
    Dougall N; Maayan N; Soares-Weiser K; McDermott LM; McIntosh A
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006081. PubMed ID: 26289586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial.
    Albert N; Randers L; Allott K; Jensen HD; Melau M; Hjorthøj C; Nordentoft M
    Psychol Med; 2019 May; 49(7):1138-1147. PubMed ID: 30058511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.